Eli Lilly and Company, incorporated in Indiana in 1901 as successor to a drug manufacturing business founded in 1876, discovers, develops, manufactures and markets human pharmaceutical products in a single business segment. Its portfolio spans cardiometabolic health products such as Mounjaro, Zepbound, Jardiance and insulins like Humalog and Humulin, and oncology products such as Cyramza, Erbitux, Jaypirca and Retevmo. Products are made in facilities in the United States (including Puerto Rico), Europe and Asia, and sold in approximately 90 countries. For 2025, revenue was $65,179 million and net income was $20,640 million.
Market cap
—
EV
—
Price—Not shown: the 10-K and 10-Q state no closing price. Shares as of 2026-10-26
LTM EV/EBITDA
—
LTM EV/EBIT
—
LTM PER
—
PBR
—
Debt to net debt (US$B)
Balance sheet as of 2026-09-30
RESULTS + BALANCE SHEET
Revenue (US$B)
EBITDA (US$B)
Net income (US$B)
Capital structure (2026-09-30)
Equity 45% / Debt 55% · D/E 1.23
Cash + ST investments vs. debt (US$B)
Cash etc.
Debt
'21/12
3.91
16.9
Net debt
'22/12
2.21
16.2
Net debt
'23/12
2.93
25.2
Net debt
'24/12
3.42
33.6
Net debt
'25/12
7.27
42.5
Net debt
EBITDA = operating income + D&A (cash flow statement). LTM = 12 months to 2026-09-30: Revenue $86.5B / EBITDA $37.2B / Net income $27.6B. Where no operating income line exists, pre-tax income plus interest expense is used
SEGMENTS
2025-12-31 · US$B · Net income
Human pharmaceutical products
Revenue65.2
Segment profit20.631.7%
Consolidated revenue
Gap to segment total = corporate and eliminations65.2
OWNERSHIP
Top 10 institutions hold 43.1% (as of 2026-06-30)
1LILLY ENDOWMENT INC9.61%
2BlackRock, Inc.7.18%
3VANGUARD CAPITAL MANAGEMENT LLC5.69%
4PNC Financial Services Group, Inc.5.46%
5STATE STREET CORP3.85%
6FMR LLC3.03%
7Capital Research Global Investors2.22%
8VANGUARD PORTFOLIO MANAGEMENT LLC2.22%
9GEODE CAPITAL MANAGEMENT, LLC2.16%
10MORGAN STANLEY1.72%
Source: Form 13F holdings as of 2026-06-30, aggregated from SEC bulk data. Percent of 941M shares outstanding across all classes as of 2026-10-26. Vanguard files separately by adviser